Figure 2
From: Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
Progression-free survival (PFS) and overall survival (OS) in 33 evaluable patients.
Figure 2 | British Journal of Cancer
From: Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
Progression-free survival (PFS) and overall survival (OS) in 33 evaluable patients.
